News
XCUR
3.990
+11.76%
0.420
Weekly Report: what happened at XCUR last week (0223-0227)?
Weekly Report · 3d ago
Weekly Report: what happened at XCUR last week (0216-0220)?
Weekly Report · 02/23 09:00
Exicure Announces New CEO and Interim CFO Appointments
TipRanks · 02/17 23:26
On Feb 11, The Board Of Directors Of Exicure Appointed Jung Soo Kim As CEO And President; Appointed Gyuyeob Lee As Interim CFO; Andy Yoo Resigns As CEO And President; Seung Ik Baik Resigned As CFO
Benzinga · 02/17 22:38
EXICURE INC - SEUNG IK BAIK RESIGNS AS CFO - SEC FILING
Reuters · 02/17 22:32
Exicure Inc. Appoints Jung Soo Kim as CEO and Gyuyeob Lee as Interim CFO
Reuters · 02/17 22:25
Weekly Report: what happened at XCUR last week (0209-0213)?
Weekly Report · 02/16 09:00
Exicure Announces Major Leadership and Board Restructuring
TipRanks · 02/10 21:48
Exicure Inc. Appoints Three New Directors as CEO and CFO Resign
Reuters · 02/10 21:26
Weekly Report: what happened at XCUR last week (0202-0206)?
Weekly Report · 02/09 09:00
Exicure announces publication of results from Phase 2 study of burixafor
TipRanks · 02/05 12:11
Exicure kündigt erfolgreiche Phase-2-Studie mit Burixafor zur schnellen Stammzellmobilisierung bei Multiplem Myelom und Lymphom an
Reuters · 02/05 12:00
Exicure Reports Phase 2 Success for Burixafor in Rapid Stem Cell Mobilization for Transplant Patients
Reuters · 02/05 12:00
Weekly Report: what happened at XCUR last week (0126-0130)?
Weekly Report · 02/02 09:00
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 01/27 21:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 01/26 17:05
Weekly Report: what happened at XCUR last week (0119-0123)?
Weekly Report · 01/26 09:00
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up
TipRanks · 01/24 13:01
Exicure Achieves Milestone in Burixafor Phase 2 Program
TipRanks · 01/22 21:44
Exicure Achieves Milestone in Collaboration with GPCR Therapeutics
Reuters · 01/22 21:29
More
Webull provides a variety of real-time XCUR stock news. You can receive the latest news about Exicure Inc through multiple platforms. This information may help you make smarter investment decisions.
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.